查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929603

二十碳五烯酸乙酯（Icosapentaethyl）医药市场按产品类型、年龄层、适应症、用途、分销管道和最终用户分類的全球预测（2026-2032年）

Icosapent Ethyl Drugs Market by Product Type, Patient Age Group, Indication, Application, Distribution Channel, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，二十碳五烯酸乙酯製药市值将达到 16.3 亿美元，到 2026 年将成长至 17.5 亿美元，到 2032 年将达到 25.6 亿美元，年复合成长率为 6.66%。

关键市场统计数据
基准年 2025 16.3亿美元
预计年份：2026年 17.5亿美元
预测年份 2032 25.6亿美元
复合年增长率 (%) 6.66%

为相关人员提供一份简明扼要的概述，阐述正在重塑二十碳五烯酸乙酯治疗格局的临床、监管、生产和商业性因素。

临床证据的不断累积、法规结构的不断改进以及支付方日益严格的审查，共同促使二十碳五烯酸（EIPA）成为现代心血管治疗的焦点。随着临床医师重新评估残余心血管风险和三酸甘油酯管理策略，高纯度EIPA製剂的治疗特性促使人们重新关注其在二级预防和血脂管理方面的应用。同时，生产商和供应商在规模化生产、品管以及循证定位等方面也面临新的挑战，以满足临床和商业性预期。

加速临床证据、支付方期望和生产现代化将如何重塑二十碳五烯酸乙酯疗法的战略格局

二十碳五烯酸乙酯的治疗和商业性格局正在经历一场变革，其驱动因素包括数据的成熟、监管的完善以及处方模式的转变。大量心血管结局研究正在阐明该药物在传统降血脂治疗之外，如何有效应对残余风险，促使临床医生重新评估二级预防策略。随着证据的积累，专业指南和学会越来越重视对患者的精细化选择，强调采用分层方法，优先考虑那些儘管接受了优化的他汀类药物治疗，但仍高三酸甘油脂血症和心血管风险升高的患者。

评估供应链、采购和商业性对2025年累积关税调整（导致跨国药品成本上升）的因应措施

2025年生效的关税政策变更为参与国际价值链的医药相关人员带来了复杂的成本和供应问题。进口关税和贸易法规的调整会影响原料药采购、製剂生产和跨境分销的经济效益。对于依赖特殊原料或外包委託製造流程的产品而言，关税导致的成本波动可能促使企业重新谈判供应商合约、重新评估其供应链布局，并考虑近岸外包或区域化策略以降低风险。

了解製剂形式、给药途径、剂型、适应症、通路、年龄层和最终用户群如何相互交织，从而影响二十碳五烯酸乙酯的临床应用和可及性。

基于细分市场的洞察揭示了二十碳五烯酸乙酯计画的临床效用、患者可及性和营运执行之间的交集。软胶囊剂型符合既定的口服降血脂治疗给药方案，有助于提高病患遵从性，并方便门诊病患取药。口服给药方式便于门诊病人使用，规范给药方案，并可整合到慢性病管理路径中，透过门诊就诊和药房续药来监测处方笺。

美洲、欧洲、中东和非洲以及亚太地区的区域差异将影响二十碳五烯酸乙酯的监管路径、支付方行为和市场接受度模式。

区域特征将对二十碳五烯酸乙酯的监管解读、支付方接受度、生产策略和临床应用产生深远影响。美洲地区是一个多元化的环境，监管机构、支付系统和专科药房在此互动，共同製定病患治疗路径。遵循临床指引和基于疗效的支付方谈判在此尤为重要。该地区的商业性策略通常强调循证价值提案和将临床终点与报销机制挂钩的合作合约模式。

评估药物研发公司、契约製造、临床研究人员、支付方和专业经销商组成的生态系统，影响着产品的可及性和生命週期执行。

二十碳五烯酸乙酯市场的竞争和策略定位反映了药物研发公司、临床证据管理机构、契约製造和专业供应合作伙伴之间的相互作用。药物研发公司透过开发、检验和传播结果数据，为临床可信度奠定了基础，这些数据能够指导处方行为和与支付方的沟通。同时，契约製造商和活性药物原料药供应商在扩大产能、品管和成本效益方面发挥关键作用，尤其是在口服软胶囊生产方面，因为口服软胶囊的生产需要专业的包封技术和稳定性方面的专业知识。

为加强证据产生、供应链韧性、支付方合作、通路优化和病患支持，经营团队应采取具体策略行动和改善营运措施。

寻求增强竞争优势的领导者应优先考虑一系列应对当前关键挑战的战术性和策略措施。首先，应投资于有针对性的证据生成，例如真实世界疗效研究、患者报告结局以及符合支付方要求的卫生经济学分析，以补充核心结局试验。这些倡议的设计应旨在为处方集、报销谈判和基于价值的合同讨论提供信息，同时解决临床医生对结果普遍适用性和长期安全性的担忧。

结合临床数据、监管资讯、专家定性访谈和供应链评估的严谨多源研究途径，确保了研究结果的可靠性和检验。

本报告的研究整合了多方面的证据，从而对二十碳五烯酸乙酯的体内分布进行了全面、深入的分析。主要内容包括对同侪审查的临床文献进行系统性回顾、分析监管核准文件和药品附加檔，以及综合分析药物警戒和安全性报告。此外，还采访了心臟病学、脂质代谢、药房营运和卫生经济学等领域的关键专家，从临床和监管观点出发，为实际应用和决策提供临床实践层面的背景资讯。

一份简洁的综合分析报告重点阐述了证据、支付方合作以及稳健的供应链将如何决定二十碳五烯酸乙酯的长期临床应用和商业性成功。

总之，二十碳五烯酸乙酯在现代心血管治疗中占据战略地位，兼具临床疗效、安全性和基于价值的定位。该疗法的未来发展将受到持续的核准后证据累积、支付方将临床结果与经济终点紧密结合的策略以及降低成本和供应风险的供应链调整的影响。积极围绕这些关键优先事项调整其临床开发、生产计划和商业化工作的相关人员，将更有利于成功管理准入途径，并实现其临床和商业目标。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 二十碳五烯酸乙酯药物市场（依产品类型划分）

  • 纯二十碳五烯酸乙酯产品
    • 乙酯胶囊
    • 乙酯软胶囊
  • 复合产品
    • 含他汀类药物的二十碳五烯酸乙酯製剂
    • 与其他降血脂药物併用：二十碳五烯酸乙酯
  • 研究和分发产品
    • 临床试验用品
    • 复方製剂

9. 依患者年龄层分類的二十碳五烯酸乙酯药物市场

  • 成人版
  • 老年人

第十章 二十碳五烯酸乙酯药物市场（依适应症划分）

  • 降低心血管风险
    • 动脉粥状硬化性心血管疾病
    • 伴随心血管危险因子的糖尿病
  • 高三酸甘油脂血症
    • 严重高三酸高三酸甘油脂血症
    • 轻度至中度高高三酸甘油脂血症

第十一章 二十碳五烯酸乙酯药物市场（依应用划分）

  • 降低心血管风险
  • 高三酸甘油脂血症

第十二章 二十碳五烯酸乙酯药物市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 二十碳五烯酸乙酯药物市场（依最终用户划分）

  • 诊所
  • 居家照护
  • 医院

第十四章 二十碳五烯酸乙酯製药市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 二十碳五烯酸乙酯类药物市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国二十碳五烯酸乙酯药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国二十碳五烯酸乙酯製药市场

第十八章 中国二十碳五烯酸乙酯医药市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alembic Pharmaceuticals Ltd.
  • Amarin Corporation plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biocon Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Himalaya Global Holdings Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Ltd.
Product Code: MRR-0A3806951846

The Icosapent Ethyl Drugs Market was valued at USD 1.63 billion in 2025 and is projected to grow to USD 1.75 billion in 2026, with a CAGR of 6.66%, reaching USD 2.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.63 billion
Estimated Year [2026] USD 1.75 billion
Forecast Year [2032] USD 2.56 billion
CAGR (%) 6.66%

A concise orientation to the clinical, regulatory, manufacturing, and commercial forces that are redefining the icosapent ethyl therapeutic landscape for stakeholders

Icosapent ethyl has emerged as a focal point in contemporary cardiovascular therapeutics, driven by a convergence of clinical evidence, evolving regulatory frameworks, and heightened payer scrutiny. As clinicians reassess strategies for residual cardiovascular risk and triglyceride management, the therapeutic profile of highly purified eicosapentaenoic acid preparations invites renewed consideration across secondary prevention and lipid management pathways. Concurrently, manufacturers and suppliers face fresh imperatives around scalability, quality controls, and evidentiary positioning to meet both clinical and commercial expectations.

This introduction frames the subsequent analysis by outlining the core dimensions that influence product development and adoption. Clinical outcomes and safety data form the foundation for therapeutic credibility, while regulatory determinations and label language shape prescribing practice and reimbursement. Manufacturing robustness and supply chain resilience determine commercial availability, and distribution strategies influence point-of-care access. Taken together, these vectors create a complex environment in which stakeholders must navigate scientific nuance, payer evidence requirements, and operational realities. The remainder of the executive summary builds on this foundation to explore transformative shifts, tariff impacts, segmentation intelligence, regional dynamics, competitive positioning, actionable recommendations, and methodological rigor.

How converging clinical evidence, payer expectations, and manufacturing modernization are reshaping the strategic environment for icosapent ethyl therapeutics

The therapeutic and commercial landscape for icosapent ethyl is undergoing transformative shifts fueled by data maturation, regulatory refinements, and changing prescribing paradigms. Robust cardiovascular outcomes research has crystallized the drug's role in addressing residual risk beyond conventional lipid-lowering therapies, prompting clinicians to re-evaluate secondary prevention strategies. As evidence has accumulated, professional guidelines and specialty societies have increasingly engaged with the nuances of patient selection, emphasizing stratified approaches that prioritize individuals with persistent hypertriglyceridemia and elevated cardiovascular risk despite optimized statin therapy.

Concurrently, payer frameworks are tightening their evidentiary expectations, placing greater emphasis on real-world effectiveness, cost-effectiveness analyses, and outcomes-based contracting. This shift compels manufacturers to generate post-approval evidence and to develop targeted value narratives that align clinical benefits with economic endpoints. On the supply side, pharmaceutical manufacturers and contract partners are investing in capacity expansion, analytical method validation, and enhanced quality-by-design practices to ensure consistent product availability and to meet tighter regulatory scrutiny. These convergent forces are accelerating strategic collaborations across clinical, commercial, and manufacturing domains, reshaping how icosapent ethyl is positioned, prescribed, and delivered to patients.

Assessing the supply chain, procurement, and commercial responses to the cumulative tariff adjustments that elevated cross-border pharmaceutical costs in 2025

Tariff policy shifts enacted in 2025 have introduced a complex layer of cost and supply considerations for pharmaceutical stakeholders operating across international value chains. Adjustments to import duties and trade regulations affect the economics of active pharmaceutical ingredient sourcing, finished dosage form manufacturing, and cross-border distribution. For products dependent on specialized raw materials or outsourced manufacturing nodes, tariff-induced cost variability can prompt renegotiation of supplier contracts, reassessment of supply chain footprints, and consideration of nearshoring or regionalization strategies to mitigate exposure.

In practical terms, manufacturers and distributors are evaluating whether to absorb incremental costs, pass them through to downstream purchasers, or modify sourcing strategies to preserve competitiveness. Procurement teams are intensifying supplier diversification efforts and increasing inventory planning sophistication to manage lead-time uncertainty. At the same time, regulatory filings and compliance documentation must adapt to reflect any changes in manufacturing location or ingredient provenance. Taken together, the cumulative tariff landscape in 2025 acts as a catalyst for structural adjustments across supply chains, commercial agreements, and manufacturing strategies, reinforcing the need for resilient, flexible planning that anticipates future trade volatility.

Uncovering how dosage form, route, strength, indication, channel, age group, and end-user segmentation converge to shape clinical use and access for icosapent ethyl

Segmentation-driven insight reveals where clinical utility, patient access, and operational execution intersect for icosapent ethyl programs. The product's formulation in softgel capsule form aligns with established oral lipid therapy delivery conventions, supporting patient adherence and straightforward dispensing at outpatient touchpoints. Oral administration facilitates use in ambulatory populations and enables integration into chronic care pathways where dosing regimens can be standardized and adherence monitored through clinic visits and pharmacy refills.

Strength differentiation between 1000 milligram and 500 milligram presentations allows prescribers to tailor regimens to patient needs and to accommodate titration strategies rooted in clinical judgment and lipid response. Application segmentation distinguishes between cardiovascular risk reduction and management of hypertriglyceridemia, highlighting the dual clinical pathways that underpin utilization discussions and value communication. Distribution channel dynamics span hospital pharmacies, online pharmacies, and retail pharmacy outlets, each presenting distinct fulfillment, patient counseling, and reimbursement interactions. Patient age group segmentation into adult and geriatric cohorts underscores the need for safety monitoring, polypharmacy considerations, and adherence support tailored to older adults. Finally, end-user segmentation across clinic, home care, and hospital settings illuminates different care pathways, monitoring intensity, and supply logistics, all of which influence patient access and clinical outcomes.

Regional nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory pathways, payer dynamics, and adoption patterns for icosapent ethyl

Regional dynamics exert a profound influence on regulatory interpretation, payer receptivity, manufacturing strategy, and clinical adoption of icosapent ethyl. The Americas present a heterogeneous landscape where regulatory authorities, payer systems, and specialty pharmacies interact to define patient pathways; here, clinical guideline engagement and outcomes-focused payer negotiations are particularly consequential. Within this region, commercial approaches often emphasize evidence-based value propositions and collaborative contracting models that align clinical endpoints with reimbursement mechanisms.

Europe, Middle East & Africa encompass jurisdictions with diverse regulatory requirements and health technology assessment frameworks, creating a patchwork of access scenarios. Manufacturers operating in this region must navigate variations in pricing negotiations, reimbursement timelines, and clinical guideline incorporation while also considering local manufacturing or importation strategies to manage cost pressures. Asia-Pacific includes rapidly evolving markets with expanding chronic disease burdens and increasing sophistication in clinical research infrastructure. In many Asia-Pacific countries, growing investment in cardiovascular prevention, expanding specialty pharmacy networks, and evolving payer mechanisms create opportunities for differentiated engagement, though local regulatory and distribution complexities require tailored market entry and lifecycle management tactics.

Evaluating the ecosystem of originators, contract manufacturers, clinical investigators, payers, and specialty distributors that shape product access and lifecycle execution

Competitive and strategic positioning within the icosapent ethyl arena reflects the interplay of originator companies, clinical evidence stewards, contract manufacturers, and specialty supply partners. Originator sponsors have anchored clinical credibility by developing, validating, and disseminating outcome data that inform prescribing behavior and payer dialogues. At the same time, contract manufacturing organizations and active pharmaceutical ingredient suppliers play a critical role in capacity scaling, quality management, and cost-efficiency, particularly for oral softgel production that requires specialized encapsulation and stability expertise.

Strategic alliances between clinical investigators, academic centers, and commercial teams have been central to building the post-approval evidence base and to exploring label-adjacent indications or subpopulation benefits. Payers and pharmacy benefit managers exert influence through utilization management policies and formulary placement criteria, incentivizing stakeholders to align around value demonstration and real-world evidence generation. Finally, specialty pharmacies and integrated care networks serve as pivotal distribution and adherence support nodes, bridging clinical prescribers and patients while facilitating monitoring and patient support programs. Together, these actors form an ecosystem whose effectiveness depends on transparent data exchange, supply reliability, and coherent value communication.

Concrete strategic actions and operational improvements for executives to fortify evidence generation, supply resilience, payer engagement, channel optimization, and patient support

Leaders seeking to strengthen their competitive position should prioritize a set of tactical and strategic initiatives that respond to current imperatives. First, invest in targeted evidence generation that complements pivotal outcomes trials with real-world effectiveness studies, patient-reported outcomes, and health economic analyses tailored to payer requirements. These efforts should be designed to inform formularies, reimbursement negotiations, and value-based contracting discussions while also addressing clinician concerns about generalizability and long-term safety.

Second, pursue supply chain resilience by diversifying API sources, validating alternative manufacturing partners, and exploring regional manufacturing footprints to mitigate tariff exposure and logistical risk. Third, refine commercialization models to reflect channel-specific requirements: hospital formularies demand different value narratives and support mechanisms than retail or online pharmacy channels, and integrated patient-support services can materially influence adherence. Fourth, engage early with payers and health technology assessment bodies to align evidentiary packages with reimbursement endpoints and to explore outcomes-based arrangements where appropriate. Finally, develop targeted provider education and patient engagement programs that emphasize appropriate patient selection, adherence strategies, and monitoring protocols to maximize therapeutic benefit and support long-term uptake.

A rigorous, multi-source research approach combining clinical, regulatory, qualitative expert interviews, and operational supply assessments to ensure robust and validated findings

The research underpinning this report integrates multiple evidence streams to produce a robust, triangulated understanding of icosapent ethyl dynamics. Primary inputs include systematic reviews of peer-reviewed clinical literature, analysis of regulatory approvals and labeling texts, and synthesis of pharmacovigilance and safety reports. These clinical and regulatory perspectives are complemented by interviews with key opinion leaders across cardiology, lipidology, pharmacy practice, and health economics, providing practitioner-level context for real-world use and decision-making.

On the commercial and operational side, the methodology incorporates structured interviews with manufacturing, procurement, and distribution stakeholders, as well as assessments of supply chain configurations and manufacturing capabilities. Payer-facing insights are derived from discussions with reimbursement specialists and from public payer policy documentation, which together inform the analysis of access barriers and contracting approaches. Data synthesis followed a transparent triangulation protocol that weighted evidence by source type and recency, and iterative validation sessions with external experts were used to refine interpretations and to ensure analytical rigor.

A concise synthesis highlighting how evidence, payer alignment, and resilient supply chains will determine long-term clinical uptake and commercial success for icosapent ethyl

In conclusion, icosapent ethyl occupies a strategic niche in contemporary cardiovascular care where clinical efficacy, safety, and value-based positioning intersect. The therapeutic's trajectory will be shaped by continued post-approval evidence generation, payer engagement strategies that credibly link clinical outcomes to economic endpoints, and supply chain adaptations that mitigate cost and availability risks. Stakeholders who proactively align their clinical development, manufacturing planning, and commercialization efforts around these imperatives will be better positioned to navigate access pathways and to realize clinical and business objectives.

Sustained focus on evidence generation, thoughtful engagement with payers and providers, and disciplined supply chain management will be the differentiators that determine which organizations capture long-term clinical relevance and operational advantage. The findings in this report offer detailed directional guidance to support those efforts and to inform strategic investments, partnerships, and tactical initiatives across the development and commercialization lifecycle.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Icosapent Ethyl Drugs Market, by Product Type

  • 8.1. Pure Icosapent Ethyl Products
    • 8.1.1. Ethyl Ester Capsules
    • 8.1.2. Ethyl Ester Softgels
  • 8.2. Combination Products
    • 8.2.1. Icosapent Ethyl With Statins
    • 8.2.2. Icosapent Ethyl With Other Lipid Modifiers
  • 8.3. Research And Compounding Products
    • 8.3.1. Clinical Trial Supplies
    • 8.3.2. Compounded Preparations

9. Icosapent Ethyl Drugs Market, by Patient Age Group

  • 9.1. Adult
  • 9.2. Geriatric

10. Icosapent Ethyl Drugs Market, by Indication

  • 10.1. Cardiovascular Risk Reduction
    • 10.1.1. Atherosclerotic Cardiovascular Disease
    • 10.1.2. Diabetes With Cardiovascular Risk Factors
  • 10.2. Hypertriglyceridemia
    • 10.2.1. Severe Hypertriglyceridemia
    • 10.2.2. Mild To Moderate Hypertriglyceridemia

11. Icosapent Ethyl Drugs Market, by Application

  • 11.1. Cardiovascular Risk Reduction
  • 11.2. Hypertriglyceridemia

12. Icosapent Ethyl Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Icosapent Ethyl Drugs Market, by End-User

  • 13.1. Clinic
  • 13.2. Home Care
  • 13.3. Hospital

14. Icosapent Ethyl Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Icosapent Ethyl Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Icosapent Ethyl Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Icosapent Ethyl Drugs Market

18. China Icosapent Ethyl Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Alembic Pharmaceuticals Ltd.
  • 19.6. Amarin Corporation plc
  • 19.7. Aurobindo Pharma Limited
  • 19.8. Bayer AG
  • 19.9. Biocon Limited
  • 19.10. Cipla Limited
  • 19.11. Dr. Reddy's Laboratories Ltd.
  • 19.12. GlaxoSmithKline plc
  • 19.13. Glenmark Pharmaceuticals Ltd.
  • 19.14. Himalaya Global Holdings Ltd.
  • 19.15. Macleods Pharmaceuticals Ltd.
  • 19.16. Merck & Co., Inc.
  • 19.17. Mylan N.V.
  • 19.18. Novartis AG
  • 19.19. Novo Nordisk A/S
  • 19.20. Pfizer Inc.
  • 19.21. Sanofi S.A.
  • 19.22. Sun Pharmaceutical Industries Ltd.
  • 19.23. Takeda Pharmaceutical Company Limited
  • 19.24. Torrent Pharmaceuticals Ltd.
  • 19.25. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ICOSAPENT ETHYL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ETHYL ESTER CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ETHYL ESTER CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ETHYL ESTER CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ETHYL ESTER SOFTGELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ETHYL ESTER SOFTGELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ETHYL ESTER SOFTGELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ICOSAPENT ETHYL WITH STATINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ICOSAPENT ETHYL WITH STATINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ICOSAPENT ETHYL WITH STATINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ICOSAPENT ETHYL WITH OTHER LIPID MODIFIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ICOSAPENT ETHYL WITH OTHER LIPID MODIFIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ICOSAPENT ETHYL WITH OTHER LIPID MODIFIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINICAL TRIAL SUPPLIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINICAL TRIAL SUPPLIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINICAL TRIAL SUPPLIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMPOUNDED PREPARATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMPOUNDED PREPARATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMPOUNDED PREPARATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DIABETES WITH CARDIOVASCULAR RISK FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DIABETES WITH CARDIOVASCULAR RISK FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DIABETES WITH CARDIOVASCULAR RISK FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY SEVERE HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY SEVERE HYPERTRIGLYCERIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY SEVERE HYPERTRIGLYCERIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY MILD TO MODERATE HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY MILD TO MODERATE HYPERTRIGLYCERIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY MILD TO MODERATE HYPERTRIGLYCERIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 203. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 207. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 242. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 243. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 246. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 249. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 251. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 253. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 254. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 255. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)